Inactive Instrument

Neurotrope, Inc.

Equities

NTRP

US64129T2078

Neurotrope, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018

March 08, 2019 at 10:03 pm

Neurotrope, Inc. announced earnings results for the full year ended December 31, 2018. For the full year, the company announced net loss was USD 11.022 million compared to USD 12.615 million a year ago. Basic loss per share from continuing operations was USD 1.37 compared to USD 1.64 a year ago.

Latest news about Neurotrope, Inc.

Neurotrope, Inc. completed the spin-off of Neurotrope Bioscience, Inc.	01/12/20	CI
Metuchen Pharmaceuticals LLC completed the acquisition of Neurotrope, Inc. from Intracoastal Capital LLC and others in a reverse merger transaction.	30/11/20	CI
Neurotrope, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	09/11/20	CI
Neurotrope, Inc Announces Dosing of the First Patient in Its Ongoing, Long-Term Phase 2 Study of Bryostatin-1 for the Treatment of Alzheimer's Disease	06/10/20	CI
Neurotrope, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	10/08/20	CI
Neurotrope, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	12/06/20	CI
Bryologyx Announces Agreements with Neurotrope to Acquire Bryostatin-1 Immuno-Oncology Data Package, Supply Synthetic Bryostatin-1	10/06/20	CI
Neurotrope, Inc. Launches New Long-Term Clinical Trial of Bryostatin with the National Institutes of Health for the Treatment of Patients with Alzheimer's Disease	28/05/20	CI
Metuchen Pharmaceuticals LLC entered into a non-binding term sheet to acquire Neurotrope, Inc. from Intracoastal Capital LLC and others for approximately $140 million in a reverse merger transaction.	17/05/20	CI
Neurotrope, Inc. intends to spin off Neurotrope Bioscience, Inc.	16/05/20	CI
Neurotrope, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	13/03/20	CI
Neurotrope, Inc. Announces Board Resignations	27/02/20	CI
Neurotrope Provides Corporate Update After Completing Bryostatin-1 Data Analysis for Advanced Alzheimer's Disease Trial	22/01/20	CI
National Institute of Health Awards $2.7 Million Grant to Neurotrope	22/01/20	CI
Neurotrope, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	12/11/19	CI
Neurotrope Reviews Strategic Alternatives to Maximize Shareholder Value	08/10/19	CI
Neurotrope, Inc. Announces Top-Line Results from Confirmatory Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease	09/09/19	CI
Neurotrope, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	08/08/19	CI
Neurotrope Concludes Data Collection in Confirmatory Phase 2 Clinical Trial of Moderately Severe to Severe Alzheimer's Disease	15/07/19	CI
Neurotrope, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	09/05/19	CI
Neurotrope, Inc. Appoints Michael Ciraolo as General Counsel and Chief Operating Officer	01/04/19	CI
Neurotrope Inc Comments on Biogen's Discontinued Phase 3 Trial in Alzheimer's Disease	21/03/19	CI
Neurotrope Inc. Completes Enrollment of Confirmatory Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease	13/03/19	CI
Neurotrope, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018	08/03/19	CI
Neurotrope Announces Cooperative Research and Development Agreement for Bryostatin-1 with the National Cancer Institute	04/02/19	CI

Chart Neurotrope, Inc.

Duration

Period

More charts

Company Profile

Neurotrope, Inc., is a biopharmaceutical company with its product candidates in pre-clinical and clinical development. The Company is focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. Bryostatin, which is a protein kinase C (PKC) Alpha and e activator, is also developed for other neurodegenerative or cognitive diseases and dysfunctions, which are in pre-clinical testing. Its second-generation PKC activators, such as the Bryologs are meant for the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury. It develops Bryostatin-1 for the treatment of Alzheimer's disease along with the rare (Orphan) diseases, such as Fragile X Syndrome and Niemann-Pick Type C.

Sector

More about the company